A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer

Aims The objective of the present study is to determine the prognostic value of clinical variables and biomarkers in patients with advanced stages of NSCLC and establish a prognostic classification of these patients. Methods For 135 patients with advanced NSCLC we determined their clinical variables...

Full description

Saved in:
Bibliographic Details
Published in:The International journal of biological markers 2012-07, Vol.27 (3), p.257-262
Main Authors: Trapé, Jaume, Montesinos, Jesus, Catot, Sílvia, Buxó, Josep, Franquesa, Josefina, Sala, Maria, Domenech, Montserrat, Sant, Francesc, Badal, Josep M, Arnau, Anna
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - analysis
Biomarkers, Tumor - blood
Carcinoma, Non-Small-Cell Lung - blood
Carcinoma, Non-Small-Cell Lung - chemistry
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Female
Humans
Lung Neoplasms - blood
Lung Neoplasms - chemistry
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Middle Aged
Neoplasm Staging
Prognosis
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims The objective of the present study is to determine the prognostic value of clinical variables and biomarkers in patients with advanced stages of NSCLC and establish a prognostic classification of these patients. Methods For 135 patients with advanced NSCLC we determined their clinical variables and their levels of CEA, CA 125, CYFRA 21–1, albumin, LDH, erythrosedimentation and leukocytes. Results Multivariate analysis identified PS (ECOG) >1, metastases, no anti-neoplastic treatment, CA 125 >35 U/mL, CYFRA 21–1 >3.3 ng/mL and leukocytes >10'000/μL, as independent prognostic factors for survival. Patients were classified into 3 groups according to the number of adverse prognostic factors (APF). One point was assigned for each APF, except for chemotherapy treatment. Patients with 0–1 APF represented our reference group: patients with 2–3 APF had HR=2.7 (95% CI: 1.5–4.6), while patients with 4–5 APF had HR=8.8 (95% CI: 4.6–16.8). This “score” maintained the differences between risk groups both in patients who received antineoplastic treatment and in those who did not. Conclusion The application of a score that includes clinical data and biomarkers may improve the prognostic classification of NSCLC patients.
ISSN:1724-6008
1724-6008
DOI:10.5301/JBM.2012.9314